Cartalax 50mg

What is Cartalax (50mg)?

Cartalax (50mg) is a synthetic, short-chain tripeptide composed of three amino acids with the sequence Ala-Glu-Asp. It is categorized as a healing and regenerative peptide and is studied for its potential regulatory effects on extracellular matrix and fibroblast signaling. The name "Cartalax" derives from its original identification as a cartilage peptide fraction during research within the Khavinson bioregulator program.

Identification Characteristics

• Chemical Formula: C₁₂H₁₉N₃O₈
• Molecular Weight: 333.29 g/mol
• Peptide Sequence: Ala-Glu-Asp

The molecule consists of a 3-amino acid sequence designed for research in cellular activity and extracellular matrix regulation. Cartalax is typically supplied with ≥99% purity, verified by analytical testing, and has been studied for its role in gene expression and fibrosis in laboratory models.

What are the key features of Cartalax (50mg)?

Cartalax (50mg) is supplied as a lyophilized peptide powder, which helps preserve stability and ensures reproducibility in laboratory settings. It is primarily used in cellular and molecular biology research, focusing on models involving connective tissue and fibroblast signaling. Key features include:

• 50 mg lyophilized peptide per vial for controlled reconstitution
• Purity ≥99%, confirmed by HPLC and MS analysis
• Defined tripeptide structure (Ala-Glu-Asp)
• Investigated in fibroblast and renal cell culture systems
• Batch-specific Certificate of Analysis (COA) available
• Designed exclusively for controlled laboratory environments
• Commonly used in experimental protocols studying extracellular matrix turnover, cellular aging markers, and gene expression patterns

For laboratory research use only.

How is Cartalax (50mg) synthesized?

Cartalax (50mg) is synthesized by solid-phase peptide synthesis (SPPS). This method ensures precise assembly of the Ala-Glu-Asp tripeptide sequence, maintaining high consistency and reproducibility across batches. Unlike larger peptide bioregulators isolated from tissue fractions, Cartalax is a fully defined, linear tripeptide with no disulfide bonds or post-translational modifications, making it straightforward to synthesize at high purity and reproducibility. After synthesis, the crude peptide is purified by reverse-phase HPLC to achieve high homogeneity. The peptide’s molecular identity and molecular weight are confirmed using mass spectrometry (MS). Certificates of Analysis (COAs) typically confirm sequence fidelity and analytical results, ensuring batch consistency for research use.

What is Cartalax (50mg) being studied for? What are its possible benefits?

Cartalax (50mg) is being studied for its potential to regulate cellular activity within connective tissue models. Research has focused on fibroblast proliferation, extracellular matrix synthesis, and gene expression patterns associated with tissue maintenance and replicative aging. In laboratory investigations, Cartalax has been studied for:

• Modulation of collagen-associated gene expression
• Regulation of matrix metalloproteinases (MMPs)
• Influence on fibroblast activation markers, such as Ki-67
• Evaluation of apoptosis-related proteins, including caspase-3
• Examination of senescence-associated markers, such as p16, p21, p53, and SIRT-6

Preclinical work has also explored transcription factors like NF-κB and AP-1, and mediators such as TGF-β and TNF-α, in cell culture systems. These findings are limited to experimental models, and no therapeutic outcomes have been established.

How does Cartalax (50mg) work in research studies?

In research settings, Cartalax functions as a short peptide signaling modulator. It is examined for its interaction with intracellular pathways involved in transcriptional regulation and protein synthesis. Its small size enables researchers to assess its influence on gene expression in cultured cells. Studies suggest that Cartalax may affect:

• Cellular proliferation signaling
• Expression of extracellular matrix proteins
• Activity of transcription factors linked to stress response
• The balance between matrix synthesis and degradation

Rather than acting as a receptor-targeted compound, Cartalax is studied as a regulatory peptide that influences downstream cellular signaling cascades. Its activity is studied strictly within controlled in vitro and experimental models.

What dosing information exists for Cartalax (50mg)?

Dosing information for Cartalax comes primarily from preclinical research. In cultured human skin fibroblasts, concentrations ranging from 0.01 to 10 nM have been evaluated over 24-hour incubation periods to assess changes in proliferation and gene expression markers. Renal tissue culture studies in animal models have used controlled peptide concentrations to examine markers such as p16, p21, p53, and SIRT-6. Some experimental murine protocols have explored microgram-per-kilogram ranges in exploratory designs; however, standardized in vivo dosing frameworks are not established. There are no approved or validated human dosing guidelines. All reported concentrations are derived from laboratory research settings.

How should Cartalax (50mg) be stored and handled?

Cartalax (50mg) should be stored as a lyophilized powder at ≤–20 °C, protected from light and moisture. Under these conditions, the product maintains a shelf life of up to 24 months. Room temperature exposure during transport is generally acceptable. After reconstitution using sterile laboratory technique, the solution may be stored at 2–8 °C for short-term use. For extended storage, aliquoting and freezing at ≤–20 °C is recommended to minimize degradation. Repeated freeze-thaw cycles should be avoided to preserve peptide stability and analytical integrity.

Where can I read more research about Cartalax (50mg)?

The following peer-reviewed publications provide additional context on AED peptide research:

1. Gutop EO, Linkova NS, Fridman NV, Kozhevnikova EO, Polyakova VO, Khavinson VK. AED peptide activates gene expression and differentiation proteins synthesis of human skin fibroblasts during replicative aging. Molekulyarnaya Meditsina (Molecular Medicine). 2022;20(2):32-38. doi:10.29296/24999490-2022-02-05
2. Khavinson VK, Linkova NS, Diatlova AS, Gutop EO, Orlova OA. Adv Gerontol. 2020;33(1):46-54.
3. Chalisova NI, Lin'kova NS, Nichik TE, Ryzhak AP, Dudkov AV, Ryzhak GA. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med. 2015;159(1):124-127. doi:10.1007/s10517-015-2906-9
4. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. Published 2021 Nov 22. doi:10.3390/molecules26227053

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.